Larson Financial Group LLC Has $252,000 Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Larson Financial Group LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 73.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 609 shares of the company’s stock after selling 1,645 shares during the quarter. Larson Financial Group LLC’s holdings in IDEXX Laboratories were worth $252,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. FSA Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $25,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $31,000. Ashton Thomas Securities LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $37,000. Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Crews Bank & Trust bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $41,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Up 1.5 %

Shares of NASDAQ:IDXX opened at $436.48 on Tuesday. The business has a fifty day simple moving average of $437.84 and a 200 day simple moving average of $448.70. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $562.25. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm has a market cap of $35.50 billion, a P/E ratio of 40.91, a P/E/G ratio of 3.41 and a beta of 1.39.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on IDXX shares. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Friday. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.